Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.

Oncotarget - 20 Jun 2015

Boleij Annemarie, Tops Bastiaan B J, Rombout Paul D M, Dequeker Elizabeth M, Ligtenberg Marjolijn J L, van Krieken J Han

Abstract excerpt

In 2013 the European Medicine Agency (EMA) restricted the indication for anti-EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene, increasing the need for reliable RAS mutation testing. We evaluated the completeness and reproducibility of RAS-testing in the Netherlands. From 17 laboratories, tumor DNA of the first 10 CRC cases tested in 2014 in routine clinical practice was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cetuximab

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to GTP Phosphohydrolases

Share to Netherlands

Share to Panitumumab

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 25944693
DOI: 10.18632/oncotarget.3804
PMCID: PMC4558179

Genes

BRAF
EGFR
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.PMID 25944693Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.Semantic proximity Read ↗

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Progress and potential of RAS mutation detection for diagnostics and companion diagnostics.Semantic proximity Read ↗

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.Semantic proximity Read ↗

Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer.Semantic proximity Read ↗

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.Semantic proximity Read ↗

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.Semantic proximity Read ↗

Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer.Semantic proximity Read ↗

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.Semantic proximity Read ↗

Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.